Skip to Main Content (Press Enter)

Logo UNICATT
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Persone
  • Pubblicazioni
  • Attività
  • Competenze

UNI-FIND
Logo UNICATT

|

UNI-FIND

unicatt.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Persone
  • Pubblicazioni
  • Attività
  • Competenze
  1. Pubblicazioni

Real-world management of trabectedin/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: A national survey

Articolo
Data di Pubblicazione:
2017
Citazione:
Ferrandina, M. G., Amadio, G., Paris, I., Distefano, M., Palluzzi, E., De Vincenzo, R. P., Ricci, C., Scambia, G., Real-world management of trabectedin/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: A national survey, <>, 2017; 27 (6): 1141-1148. [doi:10.1097/IGC.0000000000001058] [http://hdl.handle.net/10807/111685]
Abstract:
Background Trabectedin (T) plus pegylated liposomal doxorubicin (PLD) is approved for treatment of platinum-sensitive recurrent ovarian cancer (ROC). Despite the recommendations and guidelines, variations in managing T/PLD administration in routine clinical practice cannot be excluded. We aimed at setting up an Italian survey collecting data about management of T/PLD administration in ROC patients. Methods We carried out the development of a questionnaire-based survey on routine clinical practice in the management of ROC patients administered T/PLD. The survey registered the physicians' approach to modification/discontinuation of treatment, type of modifications, reasons why, and so on. The survey was transmitted to medical oncologists and gynecologic oncologists practicing in national centers/institutions. Results Fifty-eight Italian centers/institutions returned the compiled questionnaire; participants practiced at community cancer centers or hospitals (56.9%), academic institutions (36.2%), and other settings (private clinics, etc) (6.9%). There was no statistically significant difference in the distribution of practice setting according to geographic areas. Most responders were medical oncologists (84.5%) and were members (82.8%) of at least 1 scientific society or cooperative group. Almost 31.5% of responders reported interruption of the whole treatment, mostly because of toxicity (41.2%), followed by patients' choice (29.4%), or achievement of clinical benefit (23.5%). Dose reduction was referred by 47.4% of responders. Reduction of dose for both drugs was referred by 88.5% of responders, and the extent of dose reduction ranged between 10% and 30%. Conclusions This survey highlights the gaps in transposing evidence-based or consensus guidelines in the real-world management of T/PLD administration; these findings could be useful in order to focus the attention on specific knowledge and/or experience gaps and plan pertinent educational programs.
Tipologia CRIS:
Articolo in rivista, Nota a sentenza
Keywords:
Management of adverse effect; Pegylated liposomal doxorubicin; Recurrent ovarian cancer; Survey; Trabectedin; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Italy; Neoplasm Recurrence, Local; Oncologists; Ovarian Neoplasms; Polyethylene Glycols; Practice Patterns, Physicians'; Surveys and Questionnaires; Tetrahydroisoquinolines; Oncology; Obstetrics and Gynecology
Elenco autori:
Ferrandina, Maria Gabriella; Amadio, Giulia; Paris, Ida; Distefano, Mariagrazia; Palluzzi, Eleonora; De Vincenzo, Rosa Pasqualina; Ricci, Caterina; Scambia, Giovanni
Link alla scheda completa:
https://publicatt.unicatt.it/handle/10807/111685
Pubblicato in:
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Journal
  • Dati Generali
  • Aree Di Ricerca

Dati Generali

URL

http://journals.lww.com/ijgc/pages/default.aspx

Aree Di Ricerca

Settori (2)


LS7_3 - Pharmacology, pharmacogenomics, drug discovery and design, drug therapy - (2011)

Settore MED/40 - GINECOLOGIA E OSTETRICIA
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.0.0